| 000 | 01418 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250517202140.0 | ||
| 264 | 0 | _c20190916 | |
| 008 | 201909s 0 0 eng d | ||
| 022 | _a1469-8978 | ||
| 024 | 7 |
_a10.1017/S003329171800017X _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFernandez-Egea, Emilio | |
| 245 | 0 | 0 |
_aDistinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia. _h[electronic resource] |
| 260 |
_bPsychological medicine _c12 2018 |
||
| 300 |
_a2668-2675 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xadverse effects |
| 650 | 0 | 4 |
_aClozapine _xadverse effects |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 | _aCross-Sectional Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aObsessive-Compulsive Disorder _xchemically induced |
| 650 | 0 | 4 | _aPolypharmacy |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSchizophrenia _xdrug therapy |
| 650 | 0 | 4 |
_aUnited Kingdom _xepidemiology |
| 700 | 1 | _aWorbe, Yulia | |
| 700 | 1 | _aBernardo, Miguel | |
| 700 | 1 | _aRobbins, Trevor W | |
| 773 | 0 |
_tPsychological medicine _gvol. 48 _gno. 16 _gp. 2668-2675 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1017/S003329171800017X _zAvailable from publisher's website |
| 999 |
_c28097863 _d28097863 |
||